March 2013 Supplement - Endovascular Today

Table of Contents

Supplement

March 2013 Supplement

The New Era of Drug Elution Has Arrived

Experts share how the drug effect of Zilver PTX is changing SFA treatment.

In This Supplement

Download PDF

Treating Femoropopliteal Occlusive Disease

What will be the workhorse therapy to address this disease over the next 3 to 5 years?

By Gary M. Ansel, MD; William A. Gray, MD; and Dierk Scheinert, MD

Why Drug-Eluting Stents Are Cost Effective in the Superficial Femoral Artery

The importance of cost effectiveness in health care is accelerating. Implanting drug-eluting stents in the superficial femoral artery may offer a safe, effective, and economically valuable solution.

By Mark W. Burket, MD

The Challenges of Bringing Drug Elution to the US Market

Cook Medical Vice President Rob Lyles provides insight on the approval and launch process of Zilver PTX in the United States, as well as next steps in the evolution of drug-eluting therapies.

Why Drug-Eluting Stents Are My Gold Standard

Experience with patients treated with Zilver PTX.

By Hiroyoshi Yokoi, MD, and Fabrizio Fanelli, MD

Latest Issues

June 2026

May 2026

April 2026

March 2026

February 2026

View All Issues

In This Supplement

Most Read Articles